Beta Bionics, Inc. (BBNX) · Oct 27, 2026 · Earnings

Beta Bionics earnings beat as losses deepen before Mint launch

Beat — Revenue $35.5M vs approximately $33.6M consensus

Beta Bionics’ Q3 earnings beat revenue expectations and lifted 2026 guidance, but wider losses and a 3D algorithm reset keep the launch story unfinished.

Beta Bionics is a commercial-stage diabetes-device company trying to expand beyond its iLet insulin system with the Mint patch pump and next-generation algorithms, while still addressing FDA quality-system scrutiny. Its current commercial base remains heavily dependent on iLet, making the shift toward Mint and broader pharmacy reimbursement central to the story.

MetricQ3 2026Q3 2025 / prior guideRead
Revenue$35.5M$27.3MAbove published consensus of roughly $33.6M
Gross margin57.3%55.5%Improved year over year
Net loss$(24.4)M$(14.2)MLoss widened
Adjusted EBITDA$(18.9)M$(12.2)MLoss widened
2026 revenue guidance$124M–$126M$121M–$126MLow end raised; high end unchanged
Cash, cash equivalents and investments$373.6M$264.6M at Dec. 31, 2025Funding strengthened

The quarter beat on revenue, but the quality of growth is mixed. Revenue rose 30% year over year to $35.5 million, ahead of the roughly $33.6 million published consensus, while gross margin improved to 57.3% from 55.5%. However, DME-channel sales grew only 4%, and iLet sales through that channel fell to $11.6 million from $14.2 million. The growth engine was largely single-use products sold through the PBP channel, which drove total PBP revenue to $13.6 million from $6.2 million.

The business is growing faster, but spending is outrunning that growth. Operating expenses climbed to $46.9 million from $32.2 million, led by higher sales and marketing and research-and-development costs. As a result, the operating loss widened to $26.6 million from $17.0 million, while adjusted EBITDA deteriorated to negative $18.9 million from negative $12.2 million.

Guidance improved modestly, but the company is already warning about a near-term Mint transition effect. The 2026 revenue range moved from $121 million–$126 million to $124 million–$126 million, which is a low-end lift rather than a full-range upgrade. Management also disclosed that prospective iLet users could defer purchases while waiting for Mint, potentially shifting as much as $8.5 million of revenue out of the fourth quarter.

The capital raise gives Beta Bionics room to fund the product transition, but the regulatory path for its next algorithm just became less clean. The company ended the quarter with $373.6 million in cash, cash equivalents and investments after raising approximately $161.3 million net, supporting Mint manufacturing, clinical work and commercialization. But it withdrew the 3D Intelligence 510(k) application after FDA interactions and now plans to submit additional simulator-validation data in mid-Q4. Mint itself remains FDA-cleared, while the 3D algorithm launch depends on another regulatory step.

Bottom line: This was a narrow earnings beat with a small guidance lift and much better funding, but the underlying mix still shows iLet pressure, widening losses and a regulatory reset for 3D Intelligence. The event advances the commercial story, without removing the execution risk around the Mint transition and next algorithm launch.

What to watch next

Revised 3D Intelligence 510(k) submission, mid-Q4 2026

Original filing on SEC EDGAR

More Beta Bionics, Inc. news

Beta Bionics earnings beat as losses deepen before Mint launch | BBNX Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.